Jonathan M Mansbach1, Kohei Hasegawa2, Nadim J Ajami3, Joseph F Petrosino3, Pedro A Piedra4, Courtney N Tierney2, Janice A Espinola2, Carlos A Camargo2. 1. Department of Medicine, Boston Children's Hospital. 2. Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston. 3. Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology. 4. Department of Molecular Virology and Microbiology and Pediatrics, Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: LL-37 is a host defense peptide with antimicrobial and immunomodulatory properties. We examined the relation of serum LL-37 levels to the severity of bronchiolitis and viral etiology. METHODS: We performed a 17-center prospective cohort study in infants hospitalized with bronchiolitis over 3 winters (2011-2014). Site teams collected clinical data, nasopharyngeal aspirates and serum. We used real-time polymerase chain reaction to test nasopharyngeal aspirates for 16 viruses. We tested serum for LL-37. Severity of bronchiolitis was defined by intensive care use and hospital length of stay. Viral etiology was defined as respiratory syncytial virus (RSV) or rhinovirus (RV), including coinfections with other viruses. RESULTS: The median age of the 1005 enrolled infants was 3 months (interquartile range, 2-6 months). After adjustment for 12 variables, LL-37 levels in the lowest quartile, compared with the highest, were associated both with intensive care use (adjusted odds ratio [aOR], 1.97; P = .01) and longer hospital stay (1.34; P < .001). In separate multivariable models, infants with LL-37 levels in the lowest 3 quartiles, compared with the highest, were more likely to have RSV (eg, aOR, 2.6 [lowest quartile]; P < .001 [all quartiles]). By contrast, infants with the lowest 3 LL-37 quartiles were less likely to have RV (eg, aOR, 0.5 [lowest quartile]; Pall quartiles ≤ .03 [all quartiles]). CONCLUSIONS: In a large multicenter study of infants hospitalized with bronchiolitis, lower levels of serum LL-37 were associated with increased severity of illness. There was also an inverse relationship between LL-37 levels and the most common virus causing bronchiolitis, RSV. These findings highlight the role of LL-37 in the pathogenesis of bronchiolitis.
BACKGROUND: LL-37 is a host defense peptide with antimicrobial and immunomodulatory properties. We examined the relation of serum LL-37 levels to the severity of bronchiolitis and viral etiology. METHODS: We performed a 17-center prospective cohort study in infants hospitalized with bronchiolitis over 3 winters (2011-2014). Site teams collected clinical data, nasopharyngeal aspirates and serum. We used real-time polymerase chain reaction to test nasopharyngeal aspirates for 16 viruses. We tested serum for LL-37. Severity of bronchiolitis was defined by intensive care use and hospital length of stay. Viral etiology was defined as respiratory syncytial virus (RSV) or rhinovirus (RV), including coinfections with other viruses. RESULTS: The median age of the 1005 enrolled infants was 3 months (interquartile range, 2-6 months). After adjustment for 12 variables, LL-37 levels in the lowest quartile, compared with the highest, were associated both with intensive care use (adjusted odds ratio [aOR], 1.97; P = .01) and longer hospital stay (1.34; P < .001). In separate multivariable models, infants with LL-37 levels in the lowest 3 quartiles, compared with the highest, were more likely to have RSV (eg, aOR, 2.6 [lowest quartile]; P < .001 [all quartiles]). By contrast, infants with the lowest 3 LL-37 quartiles were less likely to have RV (eg, aOR, 0.5 [lowest quartile]; Pall quartiles ≤ .03 [all quartiles]). CONCLUSIONS: In a large multicenter study of infants hospitalized with bronchiolitis, lower levels of serum LL-37 were associated with increased severity of illness. There was also an inverse relationship between LL-37 levels and the most common virus causing bronchiolitis, RSV. These findings highlight the role of LL-37 in the pathogenesis of bronchiolitis.
Authors: Shawn L Ralston; Allan S Lieberthal; H Cody Meissner; Brian K Alverson; Jill E Baley; Anne M Gadomski; David W Johnson; Michael J Light; Nizar F Maraqa; Eneida A Mendonca; Kieran J Phelan; Joseph J Zorc; Danette Stanko-Lopp; Mark A Brown; Ian Nathanson; Elizabeth Rosenblum; Stephen Sayles; Sinsi Hernandez-Cancio Journal: Pediatrics Date: 2014-11 Impact factor: 7.124
Authors: Kohei Hasegawa; Jonathan M Mansbach; Nadim J Ajami; Joseph F Petrosino; Robert J Freishtat; Stephen J Teach; Pedro A Piedra; Carlos A Camargo Journal: J Allergy Clin Immunol Date: 2016-11-12 Impact factor: 10.793
Authors: Aline Schögler; Ricardo J Muster; Elisabeth Kieninger; Carmen Casaulta; Caroline Tapparel; Andreas Jung; Alexander Moeller; Thomas Geiser; Nicolas Regamey; Marco P Alves Journal: Eur Respir J Date: 2015-11-19 Impact factor: 16.671
Authors: Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis Journal: Science Date: 2011-09-01 Impact factor: 47.728
Authors: Camille E Powe; Catherine Ricciardi; Anders H Berg; Delger Erdenesanaa; Gina Collerone; Elizabeth Ankers; Julia Wenger; S Ananth Karumanchi; Ravi Thadhani; Ishir Bhan Journal: J Bone Miner Res Date: 2011-07 Impact factor: 6.741
Authors: J David Beckham; Ana Cadena; Jiejian Lin; Pedro A Piedra; W Paul Glezen; Stephen B Greenberg; Robert L Atmar Journal: J Infect Date: 2005-05 Impact factor: 6.072
Authors: Allison A Lambert; Gregory D Kirk; Jacquie Astemborski; Enid R Neptune; Shruti H Mehta; Robert A Wise; M Bradley Drummond Journal: PLoS One Date: 2014-04-17 Impact factor: 3.240
Authors: Silke M Currie; Emily Gwyer Findlay; Amanda J McFarlane; Paul M Fitch; Bettina Böttcher; Nick Colegrave; Allan Paras; Agnieszka Jozwik; Christopher Chiu; Jürgen Schwarze; Donald J Davidson Journal: J Immunol Date: 2016-02-12 Impact factor: 5.422
Authors: Christopher J Stewart; Jonathan M Mansbach; Nadim J Ajami; Joseph F Petrosino; Zhaozhong Zhu; Liming Liang; Carlos A Camargo; Kohei Hasegawa Journal: J Infect Dis Date: 2019-05-24 Impact factor: 5.226
Authors: Christopher J Stewart; Kohei Hasegawa; Matthew C Wong; Nadim J Ajami; Joseph F Petrosino; Pedro A Piedra; Janice A Espinola; Courtney N Tierney; Carlos A Camargo; Jonathan M Mansbach Journal: J Infect Dis Date: 2018-03-13 Impact factor: 5.226
Authors: Orianne Dumas; Kohei Hasegawa; Jonathan M Mansbach; Ashley F Sullivan; Pedro A Piedra; Carlos A Camargo Journal: J Allergy Clin Immunol Date: 2018-09-18 Impact factor: 10.793
Authors: Jonathan M Mansbach; Ruth J Geller; Kohei Hasegawa; Janice A Espinola; Michelle D Stevenson; Ashley F Sullivan; Carlos A Camargo Journal: JAMA Netw Open Date: 2019-07-03
Authors: Milica Milivojevic; Xiaoyu Che; Lucinda Bateman; Aaron Cheng; Benjamin A Garcia; Mady Hornig; Manuel Huber; Nancy G Klimas; Bohyun Lee; Hyoungjoo Lee; Susan Levine; Jose G Montoya; Daniel L Peterson; Anthony L Komaroff; W Ian Lipkin Journal: PLoS One Date: 2020-07-21 Impact factor: 3.240